Thanks for signing up for DividendStocks.com! It's the daily newsletter built for dividend and income investors. Before we can begin sending your daily updates, there’s one quick step left. Please confirm your subscription using the link below so our emails reach your inbox. Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Let’s get your dividend journey started! Discover Top Income-Generating Stocks Here See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
Today's Bonus Content 3 Stocks Under $5 With Strong Analyst Upside PotentialAuthored by Chris Markoch. Article Posted: 2/24/2026. 
Key Points - Grab Holdings is gaining analyst support as revenue growth and its first full year of profitability highlight long-term opportunity in Southeast Asia’s expanding digital economy.
- Vaxart offers speculative biotech upside with its oral vaccine platform targeting influenza, norovirus, and COVID-19, creating a high-risk, high-reward setup.
- ThredUp is positioned to benefit from the fast-growing resale market, with strong institutional ownership and industry forecasts pointing to sustained secondhand demand.
- Special Report: [Sponsorship-Ad-6-Format3]
As many investors rotate out of speculative penny stocks, others still embrace their risk-reward potential. Stocks trading under $5 are inherently risky: many are unprofitable and some generate little or no revenue. In most cases these are small-cap companies, which have been beaten up over the past several years. Even though the Russell 2000 shows signs of recovery, that improvement hasn't been felt across the broader small-cap sector. That could change in 2026 if the economic outlook improves: money may flow back into speculative names. As always, quality matters. One way to filter for quality is to favor stocks with positive analyst sentiment. That's true of the three below. Each lets investors establish a sizable position with modest capital while still offering meaningful upside potential over the next five years. Profitability Milestone Meets Long-Term Emerging Market Growth Emerging-market stocks could be among 2026's winners, but that hasn't held true for Grab Holdings Inc. (NASDAQ: GRAB), which is down roughly 15% year-to-date. Singapore-based Grab operates a super app combining technology, e-commerce and fintech services. One reason for the pullback is its proposed merger with the Indonesian ride-hailer, GoTo. The deal is not finalized and could face significant regulatory or legislative changes in Indonesia that might limit future earnings there. Grab missed slightly on revenue in its Q4 2025 report. Still, revenue rose 19% year-over-year, and the period marked the company's first full year of profitability. Analysts forecast roughly 120% earnings growth over the next 12 months. That helps explain the bullish sentiment. GRAB has a consensus price target of $6.47 — about 54% above the current price. High-Risk Biotech With Platform Potential Penny-stock investors often look to the biotechnology sector, where risk and reward are closely linked. One name to watch is Vaxart Inc. (OTCMKTS: VXRT). It's the only company on this list that meets the classic penny-stock definition — trading just above $0.60 per share at the time of writing. VXRT lacks heavy analyst coverage; the sole analyst to rate it in the past 12 months gave a Buy with a $2 target. Analysts commonly ignore certain biotech firms. Vaxart is clinical-stage — all its candidates remain in trials. The upside is clear: the company is testing oral vaccines for influenza, norovirus and COVID-19. Beyond convenience and eliminating needle-related reluctance, Vaxart says its oral platform may elicit a broader immune response and wider protection. Institutional ownership is about 18%, but dollar-volume inflows have outpaced outflows by roughly 10:1. Resale Tailwinds Could Turn Today’s Losses Into Tomorrow’s Gains ThredUp Inc. (NASDAQ: TDUP) is down about 33% in 2026, but over the past 12 months TDUP is up more than 66%. That suggests the recent decline may be a pullback amid investor skittishness toward unprofitable companies. In ThredUp's case the key caveat is "yet." The company runs an online consignment and thrift marketplace popular with Gen Z; revenue rose 12.5% year-over-year in its most recent quarter. ThredUp cites a GlobalData 2025 survey forecasting the U.S. secondhand market's gross merchandise value will grow at a 9% CAGR through 2029. Institutions own about 89% of TDUP. Dollar buying has outpaced selling two-to-one, and buyer counts exceed sellers three-to-one. However, short interest is roughly 17%, which can add near-term volatility. The six-analyst consensus price target is $12.50 — more than 190% above the current price.
| 
